CN103739712B - 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 - Google Patents

具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 Download PDF

Info

Publication number
CN103739712B
CN103739712B CN201310596839.1A CN201310596839A CN103739712B CN 103739712 B CN103739712 B CN 103739712B CN 201310596839 A CN201310596839 A CN 201310596839A CN 103739712 B CN103739712 B CN 103739712B
Authority
CN
China
Prior art keywords
modified
vwf
fviii
complex
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310596839.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103739712A (zh
Inventor
T·魏默
S·舒尔特
H·米兹尼尔
U·克龙塞勒
H·林德
W·朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of CN103739712A publication Critical patent/CN103739712A/zh
Application granted granted Critical
Publication of CN103739712B publication Critical patent/CN103739712B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201310596839.1A 2008-06-24 2009-06-24 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 Expired - Fee Related CN103739712B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08011429 2008-06-24
EP08011429.1 2008-06-24
CN200980123818XA CN102076855A (zh) 2008-06-24 2009-06-24 具有延长的体内半衰期的因子viii，冯·维勒布兰德因子或它们的复合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980123818XA Division CN102076855A (zh) 2008-06-24 2009-06-24 具有延长的体内半衰期的因子viii，冯·维勒布兰德因子或它们的复合物

Publications (2)

Publication Number Publication Date
CN103739712A CN103739712A (zh) 2014-04-23
CN103739712B true CN103739712B (zh) 2016-10-05

Family

ID=40042814

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310596839.1A Expired - Fee Related CN103739712B (zh) 2008-06-24 2009-06-24 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
CN200980123818XA Pending CN102076855A (zh) 2008-06-24 2009-06-24 具有延长的体内半衰期的因子viii，冯·维勒布兰德因子或它们的复合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200980123818XA Pending CN102076855A (zh) 2008-06-24 2009-06-24 具有延长的体内半衰期的因子viii，冯·维勒布兰德因子或它们的复合物

Country Status (12)

Country Link
US (2) US8575104B2 (enExample)
EP (2) EP2865760B1 (enExample)
JP (1) JP5832285B2 (enExample)
KR (2) KR101648734B1 (enExample)
CN (2) CN103739712B (enExample)
AU (1) AU2009262476C1 (enExample)
CA (1) CA2728012C (enExample)
DK (2) DK2291523T3 (enExample)
ES (2) ES2531464T3 (enExample)
PL (1) PL2291523T3 (enExample)
RU (1) RU2528855C2 (enExample)
WO (1) WO2009156137A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
RU2579977C2 (ru) * 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
ES2541369T3 (es) * 2010-02-16 2015-07-17 Novo Nordisk A/S Factor VIII recombinante modificado
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
JP2013519699A (ja) * 2010-02-16 2013-05-30 ノヴォ ノルディスク アー／エス 因子ｖｉｉｉ融合タンパク質
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
DK3412305T3 (da) 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
CN104271150A (zh) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
US20130230901A1 (en) * 2012-02-14 2013-09-05 Portola Pharmaceuticals, Inc. Process for making recombinant antidote to factor xa inhibitor
ES2651523T3 (es) 2012-02-15 2018-01-26 Csl Behring Gmbh Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada
MX369862B (es) 2012-02-15 2019-11-25 Bioverativ Therapeutics Inc Composiciones del factor viii y metodos para hacerlas y usarlas.
NZ628014A (en) * 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
CN104411716B (zh) 2012-04-24 2018-09-07 诺和诺德股份有限公司 适用于治疗血友病的化合物
RS59876B1 (sr) * 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
ES2657291T3 (es) * 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
US10231993B2 (en) 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
KR102714760B1 (ko) * 2013-06-28 2024-10-11 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
EP3013359A4 (en) * 2013-06-28 2017-01-25 Biogen MA Inc. Thrombin cleavable linker
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
DK3066119T3 (en) 2013-11-08 2018-11-12 Csl Ltd NEW PROCEDURE FOR CONCENTRATION OF THE VON WILLEBRAND FACTOR OR COMPLEXES OF IT
PT4176894T (pt) 2014-01-10 2024-05-21 Bioverativ Therapeutics Inc Proteínas quiméricas de fator viii e utilizações destas
WO2015188224A1 (en) 2014-06-13 2015-12-17 Csl Limited Improved production of recombinant von willebrand factor in a bioreactor
DE102014011653A1 (de) * 2014-06-20 2015-12-24 Ulrich Loos Nachweis von Autoantikörpern gegen den TSH-Rezeptor
WO2016000039A1 (en) 2014-07-02 2016-01-07 Csl Limited Modified von willebrand factor
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
EP3253786A4 (en) * 2015-02-06 2018-10-17 The University of North Carolina at Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
DK3265483T3 (da) 2015-03-06 2020-03-02 CSL Behring Lengnau AG Modificeret von Willebrand-faktor med forbedret halveringstid
EP4089109A3 (en) 2015-05-22 2023-03-01 CSL Behring Lengnau AG Methods for preparing modified von willebrand factor
EP3297656B1 (en) 2015-05-22 2020-01-08 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
WO2017112895A1 (en) * 2015-12-23 2017-06-29 Haplomics, Inc. F8 gene repair
KR20180094114A (ko) * 2016-01-07 2018-08-22 체에스엘 베링 리컴비넌트 퍼실리티 아게 돌연변이된 절단된 폰 빌레브란트 인자
WO2017117630A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated von willebrand factor
ES2938890T3 (es) * 2016-05-20 2023-04-17 Octapharma Ag Proteínas de fusión de VWF glucosiladas con farmacocinética mejorada
WO2017222337A1 (ko) * 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
TW201828975A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
AU2017358865A1 (en) 2016-11-11 2019-05-09 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
EP3641800B1 (en) 2017-06-22 2023-10-04 CSL Behring Lengnau AG Modulation of fviii immunogenicity by truncated vwf
US20190091298A1 (en) * 2017-07-07 2019-03-28 Baxalta Incorporated Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
JP7307047B2 (ja) 2017-07-07 2023-07-11 武田薬品工業株式会社 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
KR20200038309A (ko) * 2017-08-23 2020-04-10 체에스엘 베링 게엠베하 폰 빌레브란트 인자의 바이러스 여과 방법
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
JP2022514954A (ja) * 2018-12-23 2022-02-16 シーエスエル・ベーリング・エルエルシー キルスイッチを有するドナーｔ細胞
JP2022524291A (ja) 2019-02-01 2022-05-02 武田薬品工業株式会社 組換えＶＷＦ（ｒＶＷＦ）を使用する予防治療法
CN111592591B (zh) * 2020-06-17 2021-12-14 博雅生物制药集团股份有限公司 一种人血管性血友病因子/人凝血因子ⅷ复合物的制备方法及产物和应用
CN117720671B (zh) * 2024-01-30 2024-06-14 南通大学 具有自组装性能的重复结构单元重组蛋白ⅠAⅠB-ⅠAⅠBrQTY及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079271A1 (en) * 2000-04-12 2001-10-25 Principia Pharmaceutical Corporation Albumin fusion proteins

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
AU6455896A (en) 1995-07-11 1997-02-10 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
ATE319817T1 (de) 1996-04-24 2006-03-15 Univ Michigan Gegen inaktivierung resistenter faktor viii
US6103077A (en) * 1998-01-02 2000-08-15 De Nora S.P.A. Structures and methods of manufacture for gas diffusion electrodes and electrode components
ATE283034T1 (de) 1998-04-27 2004-12-15 Opperbas Holding Bv Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1148063A1 (de) 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
CA2434097A1 (en) 2001-01-12 2002-08-08 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii
EP2110385A1 (en) 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
JP2005535588A (ja) 2002-04-29 2005-11-24 バクスター・インターナショナル・インコーポレイテッド 第ｖｉｉｉ因子と低密度リポタンパク質レセプター関連タンパク質との相互作用のアンタゴニスト
KR20190034694A (ko) * 2002-12-09 2019-04-02 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
WO2004075923A2 (en) 2003-02-26 2004-09-10 Nektar Therapeutics Al, Corporation Polymer-factor viii moiety conjugates
HUE026384T2 (en) 2003-05-06 2016-06-28 Biogen Hemophilia Inc VII coagulation factor-FC chimeric proteins for the treatment of hemostasis disorder
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
CA2537273A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2633916T3 (es) 2004-11-12 2017-09-26 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
DK1835938T3 (da) * 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand-faktor-konjugater
KR20080007226A (ko) 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
US20090148425A1 (en) * 2005-10-28 2009-06-11 Tsukasa Ohmori Therapeutic method for blood coagulation disorder
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
JP2009532351A (ja) 2006-03-31 2009-09-10 バクスター・インターナショナル・インコーポレイテッド ペグ化第ｖｉｉｉ因子
EP1867660A1 (en) * 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
DK3896090T3 (da) 2006-06-14 2022-03-21 Csl Behring Gmbh Proteolytisk spalteligt fusionsprotein omfattende en blodkoagutionsfaktor
ES2531464T3 (es) 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
US9402754B2 (en) * 2010-05-18 2016-08-02 Abbott Cardiovascular Systems, Inc. Expandable endoprostheses, systems, and methods for treating a bifurcated lumen
CN104271150A (zh) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
CN104411716B (zh) 2012-04-24 2018-09-07 诺和诺德股份有限公司 适用于治疗血友病的化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079271A1 (en) * 2000-04-12 2001-10-25 Principia Pharmaceutical Corporation Albumin fusion proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
.2006,第96卷(第3期),第55-66页. *
PFISTERSHAMMER KATHARINA，ET AL..Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells.《THROMBOSIS AND HAEMOSTASIS&gt *
Strategies towards a longer acting factor VIII;E. L. SAENKO，et al.;《Haemophilia》;20060731;第12卷(第3期);摘要和第48页表1，第44页左栏第1段 *

Also Published As

Publication number Publication date
KR101648734B1 (ko) 2016-08-18
KR20110044978A (ko) 2011-05-03
US20110183907A1 (en) 2011-07-28
ES2654336T3 (es) 2018-02-13
KR101507718B1 (ko) 2015-04-10
RU2011102366A (ru) 2012-07-27
CA2728012A1 (en) 2009-12-30
US8575104B2 (en) 2013-11-05
RU2528855C2 (ru) 2014-09-20
US9290561B2 (en) 2016-03-22
HK1151068A1 (en) 2012-01-20
ES2531464T3 (es) 2015-03-16
CA2728012C (en) 2017-10-31
WO2009156137A1 (en) 2009-12-30
CN102076855A (zh) 2011-05-25
EP2291523A1 (en) 2011-03-09
DK2291523T3 (en) 2015-03-23
DK2865760T3 (en) 2018-01-15
AU2009262476A1 (en) 2009-12-30
CN103739712A (zh) 2014-04-23
EP2865760A1 (en) 2015-04-29
JP2011525363A (ja) 2011-09-22
KR20140090703A (ko) 2014-07-17
US20140072561A1 (en) 2014-03-13
AU2009262476C1 (en) 2016-06-02
EP2291523B1 (en) 2014-12-17
JP5832285B2 (ja) 2015-12-16
AU2009262476B2 (en) 2014-06-26
EP2865760B1 (en) 2017-10-11
PL2291523T3 (pl) 2015-05-29

Similar Documents

Publication Publication Date Title
CN103739712B (zh) 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
US9458223B2 (en) Von willebrand factor variants having improved factor VIII binding affinity
US8754194B2 (en) Modified coagulation factors with prolonged in vivo half-life
JP6474386B2 (ja) 複合体
EP1935430A1 (en) Modified coagulation factors with prolonged in vivo half-life
AU2013202564B2 (en) Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
HK1151068B (en) Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161005

Termination date: 20180624

CF01 Termination of patent right due to non-payment of annual fee